TY - JOUR
T1 - Malignant Solid Pseudopapillary Neoplasm of the Pancreas
T2 - An Orthogonal Analysis
AU - Fleming, Andrew M.
AU - Hendrick, Leah E.
AU - Yakoub, Danny
AU - Abdelhafeez, Hafeez
AU - Deneve, Jeremiah L.
AU - Langham, Max R.
AU - Glazer, Evan S.
AU - Davidoff, Andrew M.
AU - Merchant, Nipun B.
AU - Dickson, Paxton V.
AU - Murphy, Andrew J.
N1 - Publisher Copyright:
© 2023, Society of Surgical Oncology.
PY - 2024/1
Y1 - 2024/1
N2 - Background: Pancreatic solid pseudopapillary neoplasms (SPN) are generally indolent; however, some patients present with “malignant” SPN. An orthogonal analysis of multiple datasets was performed to investigate the utility of complete surgical resection (CSR) for malignant SPN. Methods: A systematic review was performed for cases of malignant SPN, defined as T4, N1, and/or M1. Malignant SPN was analyzed within the National Cancer Database (NCDB) and compared with T1-3N0M0 SPN. Predictors of malignant SPN were assessed, and treatments were analyzed by using survival analysis. Results: The systematic review yielded 164 cases of malignant SPN. Of 31 children, only one died due to malignant SPN. Among adults, CSR was associated with improved disease-specific survival (DSS) (P = 0.0002). Chemotherapy did not improve malignant SPN DSS, whether resected (P = 0.8485) or not (P = 0.2219). Of 692 adults with SPN within the NCDB, 93 (13.4%) had malignant SPN. Pancreatic head location (odds ratio [OR] 2.174; 95% confidence interval [CI] 1.136–4.166; P = 0.0186) and tumor size (OR 1.154; 95% CI 1.079–1.235; P < 0.0001) associated with the malignant phenotype. Malignant SPN predicted decreased overall survival (OS) compared with T1-3N0M0 disease (P < 0.0001). Resected malignant SPN demonstrated improved OS (P < 0.0001), including resected stage IV malignant SPN (P = 0.0003). Chemotherapy did not improve OS for malignant SPN, whether resected (P = 0.8633) or not (P = 0.5734). Within a multivariable model, resection was associated with decreased hazard of death (hazard ratio 0.090; 95% CI 0.030–0.261; P < 0.0001). Conclusions: Approximately 13% of patients with SPN present with a malignant phenotype. Pediatric cases may be less aggressive. Resection may improve survival for malignant SPN, which does not appear chemosensitive.
AB - Background: Pancreatic solid pseudopapillary neoplasms (SPN) are generally indolent; however, some patients present with “malignant” SPN. An orthogonal analysis of multiple datasets was performed to investigate the utility of complete surgical resection (CSR) for malignant SPN. Methods: A systematic review was performed for cases of malignant SPN, defined as T4, N1, and/or M1. Malignant SPN was analyzed within the National Cancer Database (NCDB) and compared with T1-3N0M0 SPN. Predictors of malignant SPN were assessed, and treatments were analyzed by using survival analysis. Results: The systematic review yielded 164 cases of malignant SPN. Of 31 children, only one died due to malignant SPN. Among adults, CSR was associated with improved disease-specific survival (DSS) (P = 0.0002). Chemotherapy did not improve malignant SPN DSS, whether resected (P = 0.8485) or not (P = 0.2219). Of 692 adults with SPN within the NCDB, 93 (13.4%) had malignant SPN. Pancreatic head location (odds ratio [OR] 2.174; 95% confidence interval [CI] 1.136–4.166; P = 0.0186) and tumor size (OR 1.154; 95% CI 1.079–1.235; P < 0.0001) associated with the malignant phenotype. Malignant SPN predicted decreased overall survival (OS) compared with T1-3N0M0 disease (P < 0.0001). Resected malignant SPN demonstrated improved OS (P < 0.0001), including resected stage IV malignant SPN (P = 0.0003). Chemotherapy did not improve OS for malignant SPN, whether resected (P = 0.8633) or not (P = 0.5734). Within a multivariable model, resection was associated with decreased hazard of death (hazard ratio 0.090; 95% CI 0.030–0.261; P < 0.0001). Conclusions: Approximately 13% of patients with SPN present with a malignant phenotype. Pediatric cases may be less aggressive. Resection may improve survival for malignant SPN, which does not appear chemosensitive.
UR - http://www.scopus.com/inward/record.url?scp=85172879767&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85172879767&partnerID=8YFLogxK
U2 - 10.1245/s10434-023-14343-0
DO - 10.1245/s10434-023-14343-0
M3 - Article
C2 - 37768414
AN - SCOPUS:85172879767
SN - 1068-9265
VL - 31
SP - 475
EP - 487
JO - Annals of surgical oncology
JF - Annals of surgical oncology
IS - 1
ER -